Biocon founder Kiran Mazumdar-Shaw has designated her niece, Claire Mazumdar, as her successor for the biopharmaceutical company. Mazumdar-Shaw, aged 73, expressed confidence in Claire, aged 37, to lead Biocon into its next growth phase. She emphasized the importance of entrusting the company to capable hands, citing Claire’s proven ability to manage a firm.
Claire Mazumdar currently serves as the founder and CEO of Bicara Therapeutics, a Nasdaq-listed company that originated from Biocon. Kiran Mazumdar-Shaw, who has no biological children, envisions a family ecosystem to support Biocon’s future endeavors. This ecosystem includes Claire’s brother, Eric Mazumdar, an AI expert at the California Institute of Technology, and her husband, Thomas Roberts, an oncologist at Massachusetts General Hospital.
As part of a comprehensive organizational restructuring, Biocon has consolidated its generics and biologics divisions, streamlined its operations, and reduced its debt. The company is concentrating on biosimilars, a significant revenue contributor, with a range of products already in the market and more in development, according to Mazumdar-Shaw. Claire, the chosen successor, holds advanced degrees in Biological Engineering, Business Administration, and Cancer Biology from prestigious institutions.
The leadership transition extends to other group companies, with Shreehas Tambe assuming the role of CEO and Managing Director of Biocon Biologics. Additionally, Siddharth Mittal is slated to lead Syngene International starting July 1. Biocon’s shares were trading slightly up at Rs 365.55 on the BSE on Tuesday.
